Who
Glenn Steele Jr.
Director
Company insider
Files Form 4 as: Director, PTC Therapeutics; Director, Wellcare Health Plans; Director, Cepheid.
In numbers
- Trades disclosed
- 107
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $5.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 29 Oct 2009
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $135K12,000 at $11.23 | filing |
| 30 Sep 2026filed 2 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $782K12,000 at $65.16 | filing |
| 30 Sep 2026filed 2 Oct 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $370K12,000 at $30.86 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $916K12,000 at $76.35 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $370K12,000 at $30.86 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $916K12,000 at $76.35 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,800 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 5 Jan 2023filed 9 Jan 2023 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jan 2023filed 9 Jan 2023 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 7 Jan 2022filed 11 Jan 2022 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Glenn Steele Jr.; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.